MedicarePartD.guide

A non-government resource built from CMS public data

HIV treatment and prevention on every 2026 Indiana Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Indiana cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
HIV treatment and prevention by 2026 Indiana Part D plan
DrugHumana Basic Rx Plan$0.00/moS5884-138Wellcare Value Script$8.60/moS4802-150Wellcare Classic$8.70/moS4802-086Humana Value Rx Plan$9.90/moS5884-194SilverScript Choice$29.70/moS5601-030HealthSpring Extra Rx$78.20/moS5617-365AARP Medicare Rx Saver from UHC$90.30/moS5921-360HealthSpring Assurance Rx$117.80/moS5617-222Humana Premier Rx Plan$125.30/moS5884-161AARP Medicare Rx Preferred from UHC$127.10/moS5921-396
Biktarvybictegravir/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Dovatodolutegravir and lamivudineTier 525%QL 30/30dTier 525%Tier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Triumeqabacavir/dolutegravir/lamivudineTier 433%QL 180/30dTier 440%Tier 427%Tier 434%QL 180/30dTier 435%Tier 430%QL 300/30dTier 442%QL 180/30dTier 430%QL 300/30dTier 450%QL 180/30dTier 434%QL 180/30d
Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 525%Tier 526%QL 30/30dTier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 533%QL 30/30dTier 531%QL 30/30d
Odefseyemtricitabine/rilpivirine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 525%Tier 526%QL 30/30dTier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 533%QL 30/30dTier 531%QL 30/30d
Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 525%Tier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Julucadolutegravir and rilpivirineTier 525%QL 30/30dTier 525%Tier 525%Tier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 533%QL 30/30dTier 531%QL 30/30d
Descovyemtricitabine and tenofovir alafenamideTier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 526%QL 30/30dTier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 533%QL 30/30dTier 531%QL 30/30d
Truvadaemtricitabine and tenofovir disoproxilNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
emtricitabine-tenofovirgeneric TruvadaTier 433%QL 30/30dTier 440%QL 30/30dTier 427%QL 30/30dTier 434%QL 30/30dTier 435%QL 30/30dTier 430%QL 30/30dTier 442%QL 30/30dTier 430%QL 30/30dTier 450%QL 30/30dTier 434%QL 30/30d
TivicaydolutegravirTier 525%QL 60/30dTier 525%Tier 525%Tier 526%QL 60/30dTier 525%Tier 430%QL 180/30dTier 525%QL 60/30dTier 430%QL 180/30dTier 533%QL 60/30dTier 531%QL 60/30d

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.